• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

嵌合免疫受体对自然杀伤细胞的重编程

Natural killer cell reprogramming with chimeric immune receptors.

作者信息

Shimasaki Noriko, Campana Dario

机构信息

Department of Paediatrics, National University of Singapore, Singapore, Singapore.

出版信息

Methods Mol Biol. 2013;969:203-20. doi: 10.1007/978-1-62703-260-5_13.

DOI:10.1007/978-1-62703-260-5_13
PMID:23296936
Abstract

Natural killer (NK) cells are emerging as a new tool for cell therapy of cancer. However, some cancer subtypes are relatively resistant to NK cell cytotoxicity. Expression of anti-CD19 chimeric signaling receptors can enhance NK-cell reactivity against CD19+ leukemia and lymphoma cells. Here we describe a method to enforce expression of such receptors in human NK cells relying on electroporation of mRNA and compare it to retroviral transduction of cDNA. These methods are applicable to the reprogramming of NK cells with chimeric receptors specific for other antigens expressed on cancer cells as well as with molecules that can modulate NK cell function.

摘要

自然杀伤(NK)细胞正成为癌症细胞治疗的一种新工具。然而,某些癌症亚型对NK细胞的细胞毒性相对耐药。抗CD19嵌合信号受体的表达可增强NK细胞对CD19+白血病和淋巴瘤细胞的反应性。在此,我们描述了一种依靠mRNA电穿孔在人NK细胞中强制表达此类受体的方法,并将其与cDNA的逆转录病毒转导进行比较。这些方法适用于用对癌细胞上表达的其他抗原具有特异性的嵌合受体以及可调节NK细胞功能的分子对NK细胞进行重编程。

相似文献

1
Natural killer cell reprogramming with chimeric immune receptors.嵌合免疫受体对自然杀伤细胞的重编程
Methods Mol Biol. 2013;969:203-20. doi: 10.1007/978-1-62703-260-5_13.
2
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.CD20特异性嵌合抗原受体的表达增强了自然杀伤细胞的细胞毒性活性,并克服了淋巴瘤和白血病细胞的自然杀伤抗性。
Cancer Immunol Immunother. 2008 Mar;57(3):411-23. doi: 10.1007/s00262-007-0383-3. Epub 2007 Aug 24.
3
A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies.一种临床适用的方法,可增强自然杀伤细胞对 B 细胞恶性肿瘤的细胞毒性。
Cytotherapy. 2012 Aug;14(7):830-40. doi: 10.3109/14653249.2012.671519. Epub 2012 Mar 29.
4
Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma.持续扩增的CAR NK-92细胞对B细胞白血病和淋巴瘤具有选择性细胞毒性。
Cytotherapy. 2017 Feb;19(2):235-249. doi: 10.1016/j.jcyt.2016.10.009. Epub 2016 Nov 22.
5
Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes.嵌合受体 mRNA 转染作为生成抗肿瘤淋巴细胞的工具。
Hum Gene Ther. 2009 Jan;20(1):51-61. doi: 10.1089/hum.2008.068.
6
Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4.自然杀伤细胞受体杀伤细胞免疫球蛋白样受体双结构域短尾4型可识别HLA - Cw4,而不能识别HLA - Cw6。
J Immunol. 2001 Jun 15;166(12):7260-7. doi: 10.4049/jimmunol.166.12.7260.
7
Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.嵌合抗原受体工程化细胞因子诱导的杀伤细胞克服前B细胞急性淋巴细胞白血病的治疗耐药性并提高生存率。
Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11.
8
Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.用于重定向自然杀伤(NK)细胞对白血病进行细胞溶解的NKp80-Fc融合蛋白的生成及临床前表征
J Biol Chem. 2015 Sep 11;290(37):22474-84. doi: 10.1074/jbc.M115.678912. Epub 2015 Jul 21.
9
Engineering of Natural Killer Cells for Clinical Application.自然杀伤细胞的临床应用工程。
Methods Mol Biol. 2020;2097:91-105. doi: 10.1007/978-1-0716-0203-4_6.
10
Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method.用一种符合监管要求的非病毒方法在自然杀伤细胞中表达嵌合抗原受体。
Cancer Gene Ther. 2010 Mar;17(3):147-54. doi: 10.1038/cgt.2009.61. Epub 2009 Sep 11.

引用本文的文献

1
Current Insights into CAR T-Cell-Based Therapies for Myelodysplastic Syndrome.基于嵌合抗原受体T细胞疗法治疗骨髓增生异常综合征的最新见解
Pharm Res. 2024 Sep;41(9):1757-1773. doi: 10.1007/s11095-024-03761-8. Epub 2024 Aug 26.
2
Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges.从癌症到侵袭性真菌感染的 NK 细胞疗法的操控:前景与挑战。
Front Immunol. 2023 Jan 11;13:1044946. doi: 10.3389/fimmu.2022.1044946. eCollection 2022.
3
NK cells for cancer immunotherapy.自然杀伤细胞用于癌症免疫疗法。
Nat Rev Drug Discov. 2020 Mar;19(3):200-218. doi: 10.1038/s41573-019-0052-1. Epub 2020 Jan 6.
4
Human CAR NK Cells: A New Non-viral Method Allowing High Efficient Transfection and Strong Tumor Cell Killing.人细胞毒性自然杀伤细胞:一种新型非病毒方法,可实现高效转染和强烈杀伤肿瘤细胞。
Front Immunol. 2019 Apr 30;10:957. doi: 10.3389/fimmu.2019.00957. eCollection 2019.
5
A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells.一种生成 T 细胞受体缺陷嵌合抗原受体 T 细胞的新方法。
Blood Adv. 2018 Mar 13;2(5):517-528. doi: 10.1182/bloodadvances.2017012823.
6
Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy.抗人间皮素靶向嵌合抗原受体信使 RNA 转染外周血淋巴细胞治疗卵巢癌的研究进展。
Hum Gene Ther. 2018 May;29(5):614-625. doi: 10.1089/hum.2017.080. Epub 2018 Apr 2.
7
Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies.阻断T细胞中CD7的表达以实现对T细胞恶性肿瘤的有效嵌合抗原受体靶向作用。
Blood Adv. 2017 Nov 21;1(25):2348-2360. doi: 10.1182/bloodadvances.2017009928. eCollection 2017 Nov 28.
8
Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.用于癌症免疫治疗的嵌合抗原受体工程化自然杀伤细胞和自然杀伤T细胞。
Transl Res. 2017 Sep;187:32-43. doi: 10.1016/j.trsl.2017.06.003. Epub 2017 Jun 9.
9
The TGF-β/SMAD pathway is an important mechanism for NK cell immune evasion in childhood B-acute lymphoblastic leukemia.转化生长因子-β/信号转导分子母亲抗五聚体蛋白1(TGF-β/SMAD)信号通路是儿童B淋巴细胞急性淋巴细胞白血病中自然杀伤(NK)细胞免疫逃逸的重要机制。
Leukemia. 2016 Apr;30(4):800-11. doi: 10.1038/leu.2015.327. Epub 2015 Dec 1.
10
Adoptive T-cell therapy for Leukemia.白血病的过继性T细胞疗法。
Mol Cell Ther. 2014 Aug 12;2:25. doi: 10.1186/2052-8426-2-25. eCollection 2014.